



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-J450 on this 12th day of December, 2003.

(Signature of person mailing)

(Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael J. Munchhof, et al. :

APPLICATION NO.: 10/667,183 : Examiner:

FILING DATE: September 17, 2003 : Group Art Unit:

TITLE: NOVEL TRIAZOLE COMPOUNDS AS

TRANSFORMING GROWTH FACTOR (TGF)

INHIBITORS

Hon. Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 (b)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in cord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).



Patent Application Attorney Docket No.PC25293A

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: December 12,2003

Christine S. Lee

Attorney for Applicant(s)

Reg. No. 42,788

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 686-2144

#67308 v1 - PC25293A INFORMATION DISCLOSURE STATEMENT

DEC 1 7 2003

DINFORMATION DISCLOSURE CITATION							ATTY. DOCKET NO. PC25293A					SERIAL NO. 10/667,183				
(Use several sheets if necessary)							APPLICANT Michael J. Munchhof, et al.									
						FI	FILING DATE September 17, 2003					GROUP				
	U.S. PATENT DOCUMENTS															
EXAMINER INITIAL	DOCUMENT NUMBE			BER	.R 		DATE	NAME		CLASS	SUBCLASS	FIUNG DATE IF APPROPRIATE				
					•											
FOREIGN PATENT DOCUMENTS																
DOCUMENT NUMBER									DATE	COUNTRY		CLASS	SUBCLASS	TRANS	LATION	
														YES	NO	
	wo	9	8	5	2	9	3	7	11/26/98	International						
	wo	9	8	5	2	9	4	1	·11/26/98	International						
1	wo	0	0	3	1	0	6	3	06/02/00	International						
	wo	0	2	6	2	7	8	7	08/15/02	International						
	wo	0	2	6	2	7	9	4	08/15/02	International						
1	wo	0	2	6	6	4	5	2	08/29/02	International						
	wo	0	2	5	5	0	7	7	07/18/02	International						
	wo	0	2	4	0	4	7	6	05/23/02	International						
1	wo	0	2	4	0	4	6	8	05/23/02	International						
	wo	0	2	1	6	3	5	9	02/28/02	International						
	wo	0	1	7	2	7	3	7	10/04/01	International						
	wo	0	1	6	2	7	5	6	08/30/01	Internationa	al					
	wo	0	0	6	1	5	7	6	10/19/00	Internationa	al					
	wo	0	3	8	7	3	0	4	10/23/03	Internationa						
			ОТН	ER DO	CUMENT	rs (Ir	ncluding A	uthor, 1	itle, Date,	Pertinent Pa	ges, l	Etc.)				
		J. Singh, et al., "Successful Shape-Based Virtual Screening: The Discovery of a Potent Inhibitor of the Type I TGFβ Receptor Kinase (ΤβRI)", Bioorganic & Medicinal Chemistry Letters, 13 (2003) 4355-4359.														
	+	1411031	kinase (1 pm) , bioorganic & Medicinal Gnemistry Letters, 13 (2003) 4355-4359.													
	+															
EXAMINE	 D				1-11-1			DATE	ONSIDERE	D	•					
E/MININE								DATEO	OHOIDENE	-						
EXAMINER	R: Initial i	f reference C	onsidered, v	hether or no	t citation is in	conforma	ance with MPEP			on if not in conforman	e and no	ot considered.	Include copy of	this form	with	

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE